PROTAC RIPK degrader-6 |
| Katalog-Nr.GC61215 |
PROTAC RIPK degrader-6 (Beispiel 1) ist ein Cereblon-basiertes PROTAC, das auf den Abbau von RIP-Kinase abzielt, wobei der RIP2-Kinase-Inhibitor Über einen Linker an einen Cereblon-Binder gebunden ist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2089205-64-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PROTAC RIPK degrader-6 (example 1) is a PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder[1].
PROTACs is useful for the targeted degradation of proteins and other polypeptides which on the one end binds to the cereblon and on the other end to the target protein (RIP2 kinase). By bringing the target protein in close proximity to the E3-Ligase, these compounds form a ternary complex leading to polyubiquitination of the target protein inducing its degradation[1].
[1]. John David Harlin, et al. Compounds for the modulation of rip2 kinase activity. WO2017046036A1.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *